Rodolphe Anty

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Yang‐Lin Liu, Helen L. Reeves, Alastair D. Burt et al. · Nature Communications · 2014 · 601 citations · Full text

Increased Adipose Tissue Expression of Hepcidin in Severe Obesity Is Independent From Diabetes and NASH

Soumeya Bekri, Philippe Gual, Rodolphe Anty et al. · Gastroenterology · 2006 · 488 citations

Obesity, Metabolic Syndrome, Inflammation +13

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

ER stress induces NLRP3 inflammasome activation and hepatocyte death

Cynthia Lebeaupin, Emma Proïcs, C H D de Bieville et al. · Cell Death and Disease · 2015 · 389 citations · Full text